亚宝药业(600351) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥771,213,413.14, representing a decrease of 3.66% compared to the same period last year[5] - Net profit attributable to shareholders was ¥112,264,323.74, an increase of 4.51% year-on-year[5] - Basic earnings per share were ¥0.1528, reflecting a year-on-year increase of 9.55%[5] - Total operating revenue for Q1 2024 was ¥771,213,413.14, a decrease of 3.6% from ¥800,499,169.06 in Q1 2023[21] - Net profit for Q1 2024 was ¥109,772,004.55, slightly up from ¥108,529,546.66 in Q1 2023, representing a growth of 1.1%[22] - Total comprehensive income for Q1 2024 reached ¥109,772,004.55, compared to ¥108,515,275.98 in Q1 2023, reflecting a slight increase[23] - Basic and diluted earnings per share for Q1 2024 were both ¥0.1528, up from ¥0.1395 in Q1 2023, indicating a growth of approximately 9.6%[23] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥279,357,773.45, showing a significant increase of 195.85% compared to the previous year[5] - Cash flow from operating activities for Q1 2024 was ¥279,357,773.45, significantly higher than ¥94,425,180.27 in Q1 2023, representing an increase of 195.5%[26] - Cash inflow from sales of goods and services was ¥738,697,890.55 in Q1 2024, compared to ¥672,430,780.12 in Q1 2023, marking an increase of 9.8%[26] - Cash outflow for operating activities totaled ¥497,501,090.53 in Q1 2024, down from ¥604,944,255.59 in Q1 2023, a decrease of 17.7%[26] - The ending balance of cash and cash equivalents as of March 31, 2024, was ¥659,775,713.49, down from ¥711,175,799.49 at the end of Q1 2023[28] - The cash and cash equivalents at the end of Q1 2024 were ¥497,750,411.55, compared to ¥558,423,930.12 at the end of Q1 2023, showing a slight decrease[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,797,110,748.40, a decrease of 1.47% from the end of the previous year[6] - The company's total assets decreased to ¥3,797,110,748.40 from ¥3,853,636,709.00, a decline of 1.5%[18] - Total liabilities increased slightly to ¥865,709,960.08 from ¥860,330,813.75, reflecting a growth of 0.4%[17] - The total liabilities decreased to ¥749,037,709.02 in Q1 2024 from ¥793,259,937.01 in Q1 2023, indicating improved financial health[34] - Total current liabilities were ¥1,000,000,000.00 as of March 31, 2024, reflecting a slight increase from the previous period[31] Shareholder Information - Shareholders' equity attributable to the parent company was ¥2,916,775,722.64, down by 2.00% compared to the previous year-end[6] - The total number of ordinary shares at the end of the reporting period was 55,834[10] - The largest shareholder, Shanxi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 12.25% of total shares[10] - The company has 10 major shareholders, with the top 3 holding a combined total of 142,000,000 shares[11] - The total number of shares held by the top 10 unrestricted shareholders is 142,000,000, with Shanxi Yabao Investment Group being the largest[11] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] - The company has not issued any new shares or made any significant changes to its capital structure in the current quarter[14] Operational Efficiency - The company reported a significant decrease in accounts receivable financing by 38.80%, primarily due to bank acceptance bill discounts[8] - The company experienced a 76.18% decrease in contract liabilities, mainly due to reduced advance payments for housing rent[8] - Government subsidies recognized in the current period increased, contributing to a 39.34% rise in other income[8] - Total operating costs decreased to ¥644,615,339.06, down 4.8% from ¥676,853,424.93 in the same period last year[21] - The company reported a decrease in inventory to ¥432,199,460.82 from ¥442,130,343.25, a reduction of 2.0%[16] - The company's financial expenses showed a significant improvement, with a net financial income of ¥181,237.54 compared to a loss of ¥2,250,799.69 in Q1 2023[22] - The financial expenses turned positive with a net financial income of ¥2,882,641.69 in Q1 2024, compared to a loss of ¥1,845,014.04 in Q1 2023[34] Research and Development - Research and development expenses rose to ¥31,012,841.20, an increase of 13.5% compared to ¥27,263,743.67 in Q1 2023[22] - Research and development expenses decreased to ¥17,239,354.39 in Q1 2024 from ¥21,078,231.83 in Q1 2023, suggesting a potential shift in focus or efficiency improvements[34] Future Outlook - The company plans to continue focusing on market expansion and new product development to sustain growth momentum in the upcoming quarters[34] - The company has not disclosed any new product developments or technological advancements in this reporting period[12] - There are no significant mergers or acquisitions reported during this quarter[12]